5-8% of all pregnant women develop preeclampsia, a syndrome characterised by hypertension and proteinuria. For the majority of women, the disease has only mild impact on the pregnancy, but for some women the disease develops uncontrolled with serious consequences for the mother and child. Termination of the pregnancy is often indicated to control the disease.

Two focus points are of clinical interest:

  1. To predict which patients are at risk of developing preeclampsia early in the pregnancy. Research shows that early supplement with low dose acetic acid (Aspirin) can protect against development of preeclampsia.  
  2. To predict the clinical development of the disease later in the pregnancy.

In our research, we aim at developing screening strategies for diseases and conditions related to preeclampsia based on biomarkers from pregnant women.

Can we predict the development of preeclampsia based on a blood sample in the first trimester?

Can we distinguish between mild and severe preeclampsia based on a blood sample?

Current main projects related to preeclampsia:

  • Development of screening strategy in the third trimester for women with symptoms of preeclampsia.
    In a biobank of approximately 400 blood samples from patients with symptoms of preeclampsia, we investigate a group of new biomarkers to predict the clinical development of the disease.
    Which patients will need clinical intervention and which will continue to have only mild symptoms that do not require clinical intervention?
  • Is preeclampsia an autoimmune disease? We investigate the prevalence of autoimmune antibodies in patients who develop preeclampsia in the third trimester.

The research is conducted in close collaboration with Department of Obstetrics and Gynecology and collaborators in Germany, England and France.

Further information:
Please contact associate professor, MSc, PhD Niels Tørring: nieltoer@rm.dk Tel: +45 4046 5710.

Revised: 5 April 2017